ARAF is altered in 3.49% of malignant peripheral nerve sheath tumor patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is altered in 3.19% of malignant peripheral nerve sheath tumor patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL is altered in 1.18% of malignant peripheral nerve sheath tumor patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EED is altered in 11.11% of malignant peripheral nerve sheath tumor patients [2].

EED is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains EED status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is altered in 1.16% of malignant peripheral nerve sheath tumor patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is altered in 1.12% of malignant peripheral nerve sheath tumor patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS is altered in 5.32% of malignant peripheral nerve sheath tumor patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is altered in 2.2% of malignant peripheral nerve sheath tumor patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is altered in 34.78% of malignant peripheral nerve sheath tumor patients [2].

NF1 is an inclusion eligibility criterion in 4 clinical trials for malignant peripheral nerve sheath tumor, of which 1 is open and 3 are closed. Of the trials that contain NF1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [3].

NRAS is altered in 3.19% of malignant peripheral nerve sheath tumor patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 6.32% of malignant peripheral nerve sheath tumor patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 4.26% of malignant peripheral nerve sheath tumor patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 1.11% of malignant peripheral nerve sheath tumor patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC is altered in 1.37% of malignant peripheral nerve sheath tumor patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains SRC status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SUZ12 is altered in 18.6% of malignant peripheral nerve sheath tumor patients [2].

SUZ12 is an inclusion eligibility criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains SUZ12 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 2 (1 open) [3].